ABBY INGENITO: Open Payments
NPI 1831801349 · GLEN MILLS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$729 in 31 payments from 15 companies in 2025. Trend: 2023 $552 · 2024 $1,264 · 2025 $729
Food & beverage: $729
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $186 |
| ABBVIE INC. | 5 | $99 |
| Exact Sciences Corporation | 3 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $46 |
| SHIELD THERAPEUTICS INC | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| Abbott Laboratories | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $30 |
Products named: Ozempic, VRAYLAR, JARDIANCE, XIFAXAN, ACCRUFER, UBRELVY, TRELEGY ELLIPTA, FREESTYLE LIBRE 3.
Industry payments across PA — which companies pay providers there.
